{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:55:28Z","timestamp":1791269728243,"version":"4.1.0"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Schizophrenia is a severe chronic mental disease with considerable prevalence and social load. Its treatment relies on both typical and atypical antipsychotics, whose primary mechanism of action involves dopamine D\n                    <jats:sub>2<\/jats:sub>\n                    receptor blockade, with atypical agents additionally modulating serotonergic pathways, which partially improves tolerability but does not adequately address cognitive symptoms. Xanomeline\u2013trospium (KarXT) is the first FDA-approved drug for schizophrenia treatment via cholinergic receptor modulation. The antipsychotic feature of xanomeline lies in its M\n                    <jats:sub>1<\/jats:sub>\n                    and M\n                    <jats:sub>4<\/jats:sub>\n                    muscarinic receptor agonism in the central nervous system. Trospium does not cross the blood\u2013brain barrier and acts as a peripheral muscarinic antagonist, thereby reducing the side effects of xanomeline, which also exerts peripheral activity. In Phase II and III clinical trials conducted between 2016 and 2023 (EMERGENT-1 to EMERGENT-5), KarXT demonstrated statistically significant reductions in psychotic symptoms, measured by the Positive and Negative Syndrome Scale compared with placebo in short-term randomized studies, with moderate effect sizes, and sustained symptom improvement and stable tolerability over 52 weeks in long-term extension trials. They also reported a favorable tolerability profile, with frequent mild gastrointestinal side effects. An important finding is that KarXT does not affect dopaminergic transmission and therefore does not cause the expected side effects typically associated with D\n                    <jats:sub>2<\/jats:sub>\n                    receptor blockers, including extrapyramidal reactions and hyperprolactinemia. This review presents the pharmacological rationale behind KarXT and the current clinical evidence for its efficacy, safety, and proposes a breakthrough in the schizophrenia therapy.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2026.1774437","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:27:12Z","timestamp":1770794832000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["From dopamine to muscarine: xanomeline-trospium (KarXT) as a novel direction in the psychopharmacotherapy of schizophrenia"],"prefix":"10.3389","volume":"17","author":[{"given":"Kacper","family":"\u017be\u0142abowski","sequence":"first","affiliation":[{"name":"Department of Forensic Medicine, Scientific Society for Psychopharmacology, Wroc\u0142aw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Pichowicz","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine, Scientific Society for Psychopharmacology, Wroc\u0142aw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Dembowska","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine, Scientific Society for Psychopharmacology, Wroc\u0142aw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Szwajkowski","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine, Scientific Society for Psychopharmacology, Wroc\u0142aw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Mykhailova","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Immunochemistry, Wroclaw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Wurm","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine, Scientific Society for Psychopharmacology, Wroc\u0142aw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Biedka","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pathophysiology, Wroc\u0142aw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"B\u0142aszczyk","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine, Scientific Society for Psychopharmacology, Wroc\u0142aw Medical University","place":["Wroc\u0142aw, Poland"]},{"name":"Department of Physiology and Pathophysiology, Wroc\u0142aw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patryk","family":"Piotrowski","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Wroc\u0142aw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.2165\/00002512-199711060-00004","article-title":"Potential role of muscarinic agonists in Alzheimer\u2019s disease","volume":"11","author":"Avery","year":"1997","journal-title":"Drugs Aging"},{"key":"B2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s40261-024-01377-9","article-title":"Current findings and potential mechanisms of KarXT (Xanomeline-Trospium) in schizophrenia treatment","volume":"44","author":"Azargoonjahromi","year":"2024","journal-title":"Clin. Drug Investig."},{"key":"B3","article-title":"Terran biosciences prepares for trials of schizophrenia drug","author":"Beaney","year":"2024","journal-title":"Clin. Trials Arena"},{"key":"B4","unstructured":"Bristol myers squibb announces topline results from phase 3 ARISE trial evaluating cobenfy (Xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with schizophrenia\n          \n          \n          2025"},{"key":"B5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00213-023-06362-2","article-title":"Evidence of trospium\u2019s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results","volume":"240","author":"Breier","year":"2023","journal-title":"Psychopharmacology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4111\/kju.2013.54.12.806","article-title":"Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects","volume":"54","author":"\u00c7etinel","year":"2013","journal-title":"Korean J. Urology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00632","article-title":"Negative symptoms of schizophrenia and dopaminergic transmission: Translational models and perspectives opened by iPSC techniques","author":"Collo","year":"2020","journal-title":"Front. Neurosci."},{"key":"B10","unstructured":"FDA approves drug with new mechanism of action for treatment of schizophrenia\n          \n          \n          2024"},{"key":"B11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41537-022-00320-1","article-title":"Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophr. (Heidelb)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1017\/s1092852923001360","article-title":"Safety and efficacy of KarXT (xanomeline trospium) in schizophrenia in the phase 3, randomized, Double-blind, placebo-Controlled EMERGENT-2 Trial","volume":"28","author":"Correll","year":"2023","journal-title":"CNS Spectrums"},{"key":"B13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neuropharm.2017.04.033","article-title":"Endocannabinoid modulation of dopamine neurotransmission","volume":"15","author":"Covey","year":"2017","journal-title":"Neuropharmacology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/bdd.1911","article-title":"Improvement of trospium-specific absorption models for fasted and fed states in humans","volume":"35","author":"Cviji\u0107","year":"2014","journal-title":"Biopharm. & Drug Dispos."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1021\/cn400086m","article-title":"Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits","volume":"4","author":"Davie","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"112989","DOI":"10.1016\/j.psychres.2020.112989","article-title":"Muscarinic M1 and M4 receptors: hypothesis driven drug development for schizophrenia","volume":"288","author":"Dean","year":"2020","journal-title":"Psychiatry Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1124333","DOI":"10.3389\/fncel.2023.1124333","article-title":"A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia","volume":"17","author":"Dean","year":"2023","journal-title":"Front. Cell Neurosci."},{"key":"B18","first-page":"463","volume-title":"Absorption, distribution, metabolism, and elimination of radiolabeled xanomeline in healthy Male subjectsAlzheimer\u2019s and parkinson\u2019s diseases: recent developments","author":"DeLong","year":"1995"},{"key":"B19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2165\/00003088-200544070-00003","article-title":"Clinical pharmacokinetics of trospium chloride","volume":"44","author":"Doroshyenko","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.euroneuro.2024.11.013","article-title":"Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: a systematic review and meta-analysis","volume":"92","author":"Fabiano","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B21","unstructured":"Label\n          \n          \n          2025"},{"key":"B22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.neuropharm.2018.01.028","article-title":"Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases","volume":"136","author":"Felder","year":"2018","journal-title":"Neuropharmacology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40267-023-00982-6","article-title":"Clozapine is the approved option in treatment-resistant schizophrenia and requires careful management","volume":"39","author":"Fenton","year":"2023","journal-title":"Drugs Ther. Perspect."},{"key":"B24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2174\/156720507783018163","article-title":"M1 muscarinic agonists target major hallmarks of alzheimers disease \u2013 an update","volume":"4","author":"Fisher","year":"2025","journal-title":"Curr. Alzheimer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"113201","DOI":"10.1016\/j.bbr.2021.113201","article-title":"Targeting muscarinic receptors to treat schizophrenia","volume":"405","author":"Foster","year":"2021","journal-title":"Behav. Brain Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12888-025-06662-1","article-title":"Is muscarinic receptor agonist effective and tolerant for schizophrenia?","volume":"25","author":"Guo","year":"2025","journal-title":"BMC Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2025.01.019","article-title":"Capturing changes in social functioning and positive affect using ecological momentary assessment during a 12-month trial of xanomeline and trospium chloride in schizophrenia","volume":"276","author":"Harvey","year":"2025","journal-title":"Schizophrenia Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e71131","DOI":"10.7759\/cureus.71131","article-title":"Cobenfy (Xanomeline-Trospium chloride): a new frontier in schizophrenia management","volume":"16","author":"Hasan","year":"2024","journal-title":"Cureus"},{"key":"B30","article-title":"Schizophrenia trospium","year":"2025","journal-title":"ICER"},{"key":"B31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.pnpbp.2017.11.004","article-title":"Side effect burden of antipsychotic drugs in real life \u2013 impact of gender and polypharmacy","volume":"82","author":"Iversen","year":"2018","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry"},{"key":"B32","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial | psychiatry and behavioral health","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B33","article-title":"Xanomeline-trospium in schizophrenia: a detailed review and comparison with the institute for clinical and economic Review\u2019s analysis","year":"2026","journal-title":"J. Manag. Care & Specialty Pharm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul","year":"","journal-title":"JAMA Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41537-025-00595-0","article-title":"Author correction: efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials","volume":"11","author":"Kaul","year":"2025","journal-title":"Schizophr. (Heidelb)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1001\/archgenpsychiatry.2010.10","article-title":"Increased synaptic dopamine function in associative regions of the striatum in schizophrenia","volume":"67","author":"Kegeles","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"B38","article-title":"TerXT: combination of xanomeline and trospium prodrugs for schizophrenia","author":"Kuntz","year":"2026","journal-title":"Psychiatr. Times"},{"key":"B39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/14656566.2024.2334424","article-title":"Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review","volume":"25","author":"Leber","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"14","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/s41386-019-0363-2","article-title":"Linking PANSS negative symptom scores with the clinical global impressions scale: understanding negative symptom scores in schizophrenia","volume":"44","author":"Leucht","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejphar.2008.08.009","article-title":"Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine","volume":"596","author":"Li","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"22","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.neubiorev.2021.11.032","article-title":"New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics","volume":"132","author":"Lobo","year":"2022","journal-title":"Neurosci. & Biobehav. Rev."},{"key":"B45","first-page":"469","volume-title":"Single and multiple dose safety, pharmacodynamics and pharmacokinetics of xanomeline, a novel muscarinic M1 agonist in healthy Male subjectsAlzheimer\u2019s and parkinson\u2019s diseases: recent developments","author":"Lucas","year":"1995"},{"key":"B46","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jpsychires.2024.11.047","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a systematic review and meta-analysis","volume":"181","author":"Menegaz de Almeida","year":"2025","journal-title":"J. Psychiatric Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"pyaf015","DOI":"10.1093\/ijnp\/pyaf015","article-title":"From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1\/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials","volume":"28","author":"Meyer","year":"2025","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","article-title":"Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists","volume":"9","author":"Mirza","year":"2003","journal-title":"CNS Drug Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/mds.27740","article-title":"Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders","volume":"34","author":"Moehle","year":"2019","journal-title":"Mov. Disord."},{"key":"B50","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12888-025-06696-5","article-title":"Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials","volume":"25","author":"Mohammed","year":"2025","journal-title":"BMC Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.biopsych.2024.03.014","article-title":"Muscarinic receptor activators as novel treatments for schizophrenia","volume":"96","author":"Paul","year":"2024","journal-title":"Biol. Psychiatry"},{"key":"B52","unstructured":"Posters share positive data on long-term treatment with xanomeline\/trospium | psychiatric times\n          \n          \n          2025"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251324642","article-title":"Xanomeline-trospium: a novel therapeutic for the treatment of schizophrenia","author":"Ramey","year":"2025","journal-title":"Armando Silva Almod\u00f3var"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2165\/00003495-200464210-00005","article-title":"Trospium chloride in the management of overactive bladder","volume":"64","author":"Rovner","year":"2004","journal-title":"Drugs"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1038\/s41380-025-03023-y","article-title":"Cholinergic system in schizophrenia: a systematic review and meta-analysis","volume":"30","author":"Saint-Georges","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"B56","article-title":"Bristol myers wins US FDA approval for new type of schizophrenia drug","author":"Satija","year":"2024","journal-title":"Reuters"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"B58","doi-asserted-by":"publisher","first-page":"653916","DOI":"10.3389\/fpsyt.2021.653916","article-title":"Assessment of the minimum clinically important difference in symptoms and functions of patients with acute schizophrenia: a post hoc analysis of an open-label, single-arm multicenter study","volume":"12","author":"Si","year":"2021","journal-title":"Front. Psychiatry"},{"key":"B59","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/0091270009345498","article-title":"Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults","volume":"50","author":"Silver","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"B60","first-page":"43","article-title":"Xanomeline and trospium: a potential fixed drug combination (FDC) for Schizophrenia-A brief review of current data","volume":"19","author":"Singh","year":"2022","journal-title":"Innov. Clin. Neurosci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2","DOI":"10.9758\/cpn.24.1253","article-title":"Xanomeline-trospium (CobenfyTM) for schizophrenia: a review of the literature","volume":"23","author":"Smith","year":"2025","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/j.1742-1241.2010.02433.x","article-title":"Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder","volume":"64","author":"Staskin","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"B63","unstructured":"TerXT\n          \n          \n          2025"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1021\/acschemneuro.9b00335","article-title":"Striatal, hippocampal, and cortical networks are differentially responsive to the M4-and M1-Muscarinic acetylcholine receptor mediated effects of xanomeline","volume":"10","author":"Thorn","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/ph17050610","article-title":"The new horizon of antipsychotics beyond the classic dopaminergic hypothesis\u2014the case of the xanomeline\u2013trospium combination: a systematic review","volume":"17","author":"Vasiliu","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B66","doi-asserted-by":"publisher","first-page":"21m14316","DOI":"10.4088\/JCP.21m14316","article-title":"Antipsychotic efficacy of KarXT (Xanomeline-Trospium): post hoc analysis of positive and negative syndrome scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study","volume":"83","author":"Weiden","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"B67","unstructured":"Schizophrenia\n          \n          \n          2026"},{"key":"B68","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.schres.2024.09.023","article-title":"A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia","volume":"274","author":"Wright","year":"2024","journal-title":"Schizophrenia Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"24m15668","DOI":"10.4088\/JCP.24m15668","article-title":"Xanomeline and trospium chloride for the treatment of agitation associated with schizophrenia: PANSS-excited component results from 3 randomized, double-blind, placebo-controlled EMERGENT trials","volume":"86","author":"Yeung","year":"2025","journal-title":"J. Clin. Psychiatry"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.tips.2022.09.006","article-title":"Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic","volume":"43","author":"Yohn","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1055\/s-0032-1304649","article-title":"Pharmacokinetic and bioequivalence studies of trospium chloride after a single-dose administration in healthy Chinese volunteers","volume":"62","author":"Zhang","year":"2012","journal-title":"Arzneimittelforschung"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1774437\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:27:14Z","timestamp":1770794834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1774437\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":71,"alternative-id":["10.3389\/fphar.2026.1774437"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1774437","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1774437"}}